Article Details
Retrieved on: 2024-03-21 16:16:48
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a trial for Enspryng, a biopharma drug by Roche and Chugai Pharmaceutical for myasthenia gravis, which did not meet expectations, impacting the competitive landscape for treatments like monoclonal antibodies and orphan drugs.
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here